A recent study from the University of Pennsylvania indicates that GLP-1 receptor agonists, commonly used for weight loss and diabetes management, are effective and safe for patients with inflammatory bowel disease (IBD), exhibiting a similar safety profile to that in the general population. Patients treated with GLP-1s like semaglutide and liraglutide showed an average weight reduction of over 5% in 12 weeks, with significant declines in C-reactive protein (CRP) levels, hinting at potential anti-inflammatory effects. With obesity linked to severe IBD phenotypes and complications, researchers believe GLP-1s could offer a valuable addition to IBD treatment plans, although further longitudinal studies are needed to confirm their role in promoting long-term remission and endoscopic healing.
Study Finds GLP-1s Safe and Effective For Managing Obesity in Patients With IBD (GI & Endoscopy News)
0